Patents Assigned to FIREBRICK PHARMA LIMITED
  • Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
    Patent number: 11969441
    Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: April 30, 2024
    Assignee: FIREBRICK PHARMA LIMITED
    Inventors: Peter Molloy, Stephen Goodall
  • IMPROVED VIRUCIDAL FORMULATIONS
    Publication number: 20230233600
    Abstract: The present invention is directed to PVP-I formulations having enhanced virucidal activity. The formulations are intended for topical administration for treatment and/or decreased risk of microbial infections in subjects. The formulations include PVP-I and other ingredients selected to enhance the virucidal activity of the formulation over PVP-I alone.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Applicant: FIREBRICK PHARMA LIMITED
    Inventors: Peter MOLLOY, Simon TUCKER, Stephen GOODALL
  • PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES
    Publication number: 20220168338
    Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 2, 2022
    Applicant: FIREBRICK PHARMA LIMITED
    Inventors: Peter MOLLOY, Stephen GOODALL
  • PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES
    Publication number: 20220088067
    Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: FIREBRICK PHARMA LIMITED
    Inventors: Peter MOLLOY, Stephen GOODALL
  • Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
    Patent number: 11246887
    Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: February 15, 2022
    Assignee: FIREBRICK PHARMA LIMITED
    Inventors: Peter Molloy, Stephen Goodall
  • Treatment and prevention of the common cold using povidone-iodine
    Patent number: 11000542
    Abstract: The present invention provides a method of treating and preventing the common cold and associated secondary illnesses in a human subject, when the common cold is caused by viruses. The method comprises applying to the nasal passages of the human subject at ambient temperature, an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than 2.5% in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: May 11, 2021
    Assignee: FIREBRICK PHARMA LIMITED
    Inventors: Stephen Goodall, Peter Molloy